DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
-
- STATUS
- Recruiting
-
- End date
- Sep 7, 2024
-
- participants needed
- 600
-
- sponsor
- Daiichi Sankyo, Inc.
Updated on 13 January 2021
lapatinib
capecitabine
HER2
trastuzumab
adjuvant therapy
erbb2
her2/neu-positive breast cancer
immunostimulant
mammogram
Summary
This study will compare DS 8201a to standard treatment.
Participants must have HER2 breast cancer that has been treated before.
Their cancer:
- cannot be removed by an operation
- has spread to other parts of the body
Description
The study is designed to compare DS 8201a versus standard of care (investigator's choice) in subjects with unresectable and/or metastatic breast cancer previously treated with T-DM1.
Details
| Treatment | Capecitabine, Trastuzumab, Lapatinib, Trastuzumab deruxtecan |
|---|---|
| Clinical Study Identifier | NCT03523585 |
| Sponsor | Daiichi Sankyo, Inc. |
| Last Modified on | 13 January 2021 |
How clear was the trial content above?
Hard
Easy
Adding a note
Select a piece of text and start making personal notes.
Similar trials to consider
Loading...
Browse trials for
lapatinib
capecitabine
HER2
trastuzumab
adjuvant therapy
erbb2
her2/neu-positive breast cancer
immunostimulant
mammogram
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer